Table 2. Evolution of metabolic markers in patient 1 over a period of 6 months of metreleptin treatment.
For data before treatment, values are given as the ranges observed over the last past 3 years. AST: aspartate aminotransferase, ALT: alanine aminotransferase, ALP: alkaline phosphatase, GGT: gamma glutamyl transpeptidase.
| Before metreleptin | After 3 month metreleptin therapy (5 mg/day) | After 6 month metreleptin therapy (7.5 mg/day) | |
|---|---|---|---|
| Anthropometric markers | |||
| Weight | 53 | 51 | 50 |
| BMI | 20.2 | 19.4 | 18.9 |
| Glucose homeostasis | |||
| HbA1c (%) (N: 4–6%) |
11.6–16.5 | 7.9 | 7.3 |
| Liver assessment | |||
| AST (IU/L) N: 17–27 IU/L |
83–120 | 57 | 54 |
| ALT (IU/L) N: 11–26 IU/L |
81–148 | 50 | 59 |
| ALP (IU/L) N: 35–105 IU/L |
100–110 | 92 | 102 |
| GGT (IU/L) N: 8–36 IU/L |
170–320 | 58 | 67 |
| Steatosis (SteatoTest) | Low-grade (S1) |
Not detectable (S0) |
Low grade (S1) |
| Fibrosis (FibroTest) | Intermediate grade (F1–F2) |
Not detectable (F0) |
Not detectable (F0) |
| Necrotic and inflammatory activity (ActiTest) | Intermediate grade (A1–A2) |
very low grade (A0–A1) |
Low grade (A1) |
| Lipid profile | |||
| Triglycerides (mmol/L) (N: 0.4–1.7 mmol/L) |
1.3–2.7 | 2.0 | 1.6 |
| Insulin requirement | |||
| Human insulin (daily doses – IU/kg) | 2.9 | 2 | 1.65 |